Evoke Pharma Inc
$ 11.00
0.00%
17 Dec - close price
- Market Cap 18,946,500 USD
- Current Price $ 11.00
- High / Low $ 11.00 / 11.00
- Stock P/E N/A
- Book Value 1.56
- EPS -1.38
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.22 %
- ROE -1.35 %
- 52 Week High 25.85
- 52 Week Low 1.94
About
Evoke Pharma, Inc. is a forward-thinking specialty pharmaceutical company based in Solana Beach, California, focused on addressing significant unmet medical needs in gastroenterology. The company's leading product, Gimoti, represents a novel nasal formulation of metoclopramide aimed at treating gastroparesis in diabetic patients, highlighting Evoke's commitment to innovative therapeutic advancements. With a strategic vision to broaden its gastrointestinal portfolio, Evoke is positioned to capitalize on the increasing demand for specialized treatments, potentially driving substantial growth and enhancing patient outcomes. As the specialty pharmaceutical landscape evolves, Evoke's unique product offerings and emphasis on targeted drug development may yield compelling opportunities for investors.
Analyst Target Price
$18.00
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-10 | 2025-08-14 | 2025-05-12 | 2025-03-12 | 2024-11-07 | 2024-08-08 | 2024-05-14 | 2024-03-14 | 2023-11-09 | 2023-08-10 | 2023-05-15 | 2023-03-21 |
| Reported EPS | -0.45 | -0.62 | -0.51 | -0.77 | -0.94 | -0.9294 | -0.17 | -0.59 | -0.51 | -0.56 | -0.67 | -0.53 |
| Estimated EPS | -0.45 | -0.3 | -0.33 | -0.63 | -0.38 | -0.72 | -0.21 | -0.5 | -0.62 | -0.73 | -0.58 | -0.53 |
| Surprise | 0 | -0.32 | -0.18 | -0.14 | -0.56 | -0.2094 | 0.04 | -0.09 | 0.11 | 0.17 | -0.09 | 0 |
| Surprise Percentage | 0% | -106.6667% | -54.5455% | -22.2222% | -147.3684% | -29.0833% | 19.0476% | -18% | 17.7419% | 23.2877% | -15.5172% | 0% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: EVOK
2025-12-26 03:05:00
Evoke Pharma, a Micro Cap in the Pharmaceuticals sector, achieved a remarkable 124.49% return over the past year, making it a top performer in its sector. Other notable performers include Lexicon Pharmaceuticals, RF Industries, and DLocal Ltd., highlighting diverse investment opportunities across Pharmaceuticals, Electronics, and Software sectors. These companies showcased significant returns for investors in the last year.
2025-12-24 03:27:00
Evoke Pharma, Inc. achieved a 340.0% return in the Pharmaceuticals & Biotechnology sector over the past six months, leading a group of strong stock performers. Other notable companies include DLocal Ltd. with a 39.08% return and Arbutus Biopharma Corp. with 37.24% growth, highlighting diverse investment opportunities across various sectors. The article details the impressive returns of several companies, showcasing their performance and market capitalization.
2025-12-21 01:10:24
Evoke Pharma (formerly NASDAQ: EVOK) and QOL Medical announced the expiration of QOL-EOS Merger Sub's tender offer to acquire all outstanding shares of Evoke for $11.00 per share in cash. The tender offer closed on December 15, 2025, with approximately 67.63% of shares tendered, after which Evoke became a wholly-owned subsidiary of QOL Medical and has ceased trading on Nasdaq.
2025-12-18 10:09:16
Evoke Pharma and QOL Medical announced the expiration of QOL Medical's tender offer to acquire all outstanding shares of Evoke for $11.00 per share. Approximately 67.63% of Evoke's shares were tendered, leading to a merger where Evoke became a wholly-owned subsidiary of QOL Medical. Evoke's common stock has ceased trading on Nasdaq and will be delisted.
2025-12-18 03:09:16
Evoke Pharma Inc. (NASDAQ:EVOK) announced its acquisition by QOL Medical, LLC, which has resulted in Evoke Pharma becoming a wholly-owned subsidiary of QOL Medical. This transaction, completed on December 17, 2025, involved a tender offer for $11.00 per share in cash, with subsequent delisting of Evoke Pharma's common stock from Nasdaq and suspension of its SEC reporting obligations. Executive leadership and the board of directors of Evoke Pharma have resigned as part of the merger.
2025-12-18 03:09:12
Evoke Pharma (NASDAQ:EVOK) has been acquired by QOL Medical, LLC for $11.00 per share in cash, with approximately 67.63% of shares tendered. Following the merger, Evoke Pharma will be delisted from Nasdaq, and its registration with the SEC will be terminated. This all-cash transaction, representing a 139.7% premium over Evoke's closing price on November 3, 2025, leads to significant leadership changes at Evoke Pharma as it becomes a wholly owned subsidiary of QOL Medical.
